血栓栓塞栓性疾病中的纤维溶解剂:历史观点和已批准的指示

相关实验视频

Updated: Jul 1, 2025

07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.7K

Sina Rashedi¹, Christie M Greason², Parham Sadeghipour^1,3

¹Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

Seminars in thrombosis and hemostasis

|March 1, 2024

概括

纤维溶解剂,如高高和高,通过激活等离子体来溶解血块. 本综述涵盖了它们的历史和FDA批准的用于血栓栓塞性疾病的用途.

科学领域:

药理学药理学是指药理学的学科.
生物化学生物化学
血栓形成研究研究

背景情况:

纤维溶解剂将等离子素转化为等离子素,降解血栓并重新打开血管.
关键的药物包括链酶,尿酶和组织等离子素激活剂 (tPA).
再组合DNA技术使得阿尔特酶的产生成为可能,而基酶和基酶等衍生物是为了改善药理动力学而开发的.

研究的目的:

为了提供纤维解质剂的历史概述.
总结了在血栓栓塞性疾病中使用纤维溶解药物的批准指示.

主要方法:

关于历史发现和药物开发的文献综述.
关键纤维解质剂的FDA批准的适用情况摘要.

主要成果:

纤维溶解剂的开发范围从链杆激酶 (1933年) 到重组tPA衍生物.
阿尔特普拉斯被FDA批准用于肺栓塞,STEMI,缺血性中风和器械闭塞.
雷特和基被FDA批准用于STEMI治疗.

结论:

纤维溶解剂已经显著发展,为血栓栓塞事件提供了关键的治疗方法.
目前的药物,如阿尔特等, reteplase,和tenecteplase对于管理心血管和脑血管紧急情况至关重要.

相关概念视频

01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

696

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

696

01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

1.2K

01:16

Clot Retraction and Fibrinolysis

5.9K

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

5.9K

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

523

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

523

01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.8K

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...

2.8K

01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

181

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

181